204 related articles for article (PubMed ID: 35266655)
1. Cutting Edge: Topical Recombinant Nerve Growth Factor for the Treatment of Neurotrophic Keratopathy-Biologicals as a Novel Therapy for Neurotrophic Keratopathy.
Hamrah P; Yavuz Saricay L; Ozmen MC
Cornea; 2022 Jun; 41(6):673-679. PubMed ID: 35266655
[TBL] [Abstract][Full Text] [Related]
2. Cenegermin for the treatment of neurotrophic keratitis.
Sacchetti M; Bruscolini A; Lambiase A
Drugs Today (Barc); 2017 Nov; 53(11):585-595. PubMed ID: 29451275
[TBL] [Abstract][Full Text] [Related]
3. Topical Recombinant Human Nerve Growth Factor (Cenegermin) for Neurotrophic Keratopathy: A Multicenter Randomized Vehicle-Controlled Pivotal Trial.
Pflugfelder SC; Massaro-Giordano M; Perez VL; Hamrah P; Deng SX; Espandar L; Foster CS; Affeldt J; Seedor JA; Afshari NA; Chao W; Allegretti M; Mantelli F; Dana R
Ophthalmology; 2020 Jan; 127(1):14-26. PubMed ID: 31585826
[TBL] [Abstract][Full Text] [Related]
4. Successful Treatment of a Pediatric Neurotrophic Keratopathy With Cenegermin.
Papadopoulos K; Besgen V; Sekundo W
Cornea; 2021 Apr; 40(4):516-518. PubMed ID: 32947402
[TBL] [Abstract][Full Text] [Related]
5. Neurotrophic keratopathy.
Dua HS; Said DG; Messmer EM; Rolando M; Benitez-Del-Castillo JM; Hossain PN; Shortt AJ; Geerling G; Nubile M; Figueiredo FC; Rauz S; Mastropasqua L; Rama P; Baudouin C
Prog Retin Eye Res; 2018 Sep; 66():107-131. PubMed ID: 29698813
[TBL] [Abstract][Full Text] [Related]
6. The molecular basis of neurotrophic keratopathy: Diagnostic and therapeutic implications. A review.
Ruiz-Lozano RE; Hernandez-Camarena JC; Loya-Garcia D; Merayo-Lloves J; Rodriguez-Garcia A
Ocul Surf; 2021 Jan; 19():224-240. PubMed ID: 33022412
[TBL] [Abstract][Full Text] [Related]
7. Eight months follow-up of corneal nerves and sensitivity after treatment with cenegermin for neurotrophic keratopathy.
Pedrotti E; Bonacci E; Chierego C; De Gregorio A; Cozzini T; Brighenti T; Caldarella G; Pastore G; Fasolo A; Marchini G
Orphanet J Rare Dis; 2022 Feb; 17(1):63. PubMed ID: 35189948
[TBL] [Abstract][Full Text] [Related]
8. Cenegermin: A Review in Neurotrophic Keratitis.
Deeks ED; Lamb YN
Drugs; 2020 Apr; 80(5):489-494. PubMed ID: 32185680
[TBL] [Abstract][Full Text] [Related]
9. Clinical and instrumental assessment of the corneal healing in moderate and severe neurotrophic keratopathy treated with rh-NGF (Cenegermin).
Roszkowska AM; Inferrera L; Aragona E; Gargano R; Postorino EI; Aragona P
Eur J Ophthalmol; 2022 Nov; 32(6):3402-3410. PubMed ID: 35473440
[TBL] [Abstract][Full Text] [Related]
10. Topical cenegermin 0.002% for pediatric neurotrophic keratopathy.
Elhusseiny AM; Traish AS; Saeed HN; Mantagos IS
Eur J Ophthalmol; 2022 Nov; 32(6):3420-3424. PubMed ID: 35469461
[TBL] [Abstract][Full Text] [Related]
11. Acute Calcific Band Keratopathy as an Adverse Effect of Recombinant Human Nerve Growth Factor (Cenegermin): A Multicenter Case Series.
Qureshi S; Ferguson TJ; Lim M; You JY; Goshe JM; Hood CT
Cornea; 2022 Jan; 41(1):52-59. PubMed ID: 34582138
[TBL] [Abstract][Full Text] [Related]
12. Recombinant Human Nerve Growth Factor for Pediatric Neurotrophic Keratopathy.
Niruthisard D; Fung SSM
Eye Contact Lens; 2022 Jul; 48(7):303-305. PubMed ID: 35726907
[TBL] [Abstract][Full Text] [Related]
13. Long-term clinical efficacy of topical treatment with recombinant human nerve growth factor in neurotrophic keratopathy: a novel cure for a rare degenerative corneal disease?
Bruscolini A; Marenco M; Albanese GM; Lambiase A; Sacchetti M
Orphanet J Rare Dis; 2022 Feb; 17(1):57. PubMed ID: 35172847
[TBL] [Abstract][Full Text] [Related]
14. Advances in the Medical Management of Neurotrophic Keratitis.
Dohlman TH; Singh RB; Dana R
Semin Ophthalmol; 2021 May; 36(4):335-340. PubMed ID: 33705259
[TBL] [Abstract][Full Text] [Related]
15. Neurotrophic Keratopathy in Pediatric Patients.
Scelfo C; Mantagos IS
Semin Ophthalmol; 2021 May; 36(4):289-295. PubMed ID: 33755526
[No Abstract] [Full Text] [Related]
16. Neurotrophic keratopathy: current challenges and future prospects.
NaPier E; Camacho M; McDevitt TF; Sweeney AR
Ann Med; 2022 Dec; 54(1):666-673. PubMed ID: 35243932
[TBL] [Abstract][Full Text] [Related]
17. [Pathogenesis and epidemiology of neurotrophic keratopathy].
Mertsch S; Alder J; Dua HS; Geerling G
Ophthalmologe; 2019 Feb; 116(2):109-119. PubMed ID: 30478498
[TBL] [Abstract][Full Text] [Related]
18. Topical Nerve Growth Factor for the Treatment of Neurotrophic Keratopathy Caused by Wallenberg Syndrome.
Mandarà E; Brocca D; Pellegrini F; Interlandi E
Cornea; 2022 May; 41(5):647-648. PubMed ID: 34759201
[TBL] [Abstract][Full Text] [Related]
19. [Modern capabilities in diagnosis and treatment of neurotrophic keratopathy].
Brzheskiy VV; Popov VY; Efimova EL; Golubev SY
Vestn Oftalmol; 2022; 138(6):123-132. PubMed ID: 36573956
[TBL] [Abstract][Full Text] [Related]
20. Recent innovations with drugs in clinical trials for neurotrophic keratitis and refractory corneal ulcers.
Bremond-Gignac D; Daruich A; Robert MP; Chiambaretta F
Expert Opin Investig Drugs; 2019 Nov; 28(11):1013-1020. PubMed ID: 31596151
[No Abstract] [Full Text] [Related]
[Next] [New Search]
